Granules India Ltd
NSE:GRANULES
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
392.1
718.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Granules India Ltd
Granules India Ltd
Cost of Revenue
Granules India Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Granules India Ltd
NSE:GRANULES
|
Cost of Revenue
-₹18.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cost of Revenue
-₹88.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cost of Revenue
-₹87.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cost of Revenue
-₹104.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cost of Revenue
-₹27.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cost of Revenue
-₹34B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Granules India Ltd
Glance View
In the bustling corridors of the pharmaceutical world, Granules India Ltd. has carved out a distinctive niche through its unwavering commitment to efficiencies and economies of scale. Founded in 1984, the company began its journey as an operator of a small Paracetamol facility and steadily evolved into a formidable player on the global stage. Granules India's business model is streamlined; it meticulously integrates its manufacturing processes, focusing primarily on Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosage Forms (FDFs). By leveraging vertically integrated operations, the company ensures a seamless transition from raw material to finished product, reducing costs while maintaining high standards of product quality, an achievement that distinguishes it in the competitive landscape. Granules India capitalizes on its robust manufacturing infrastructure, which operates round the clock to serve a diverse clientele spanning across regulated and semi-regulated markets. This emphasis on cost-effective production is coupled with strategic geographical placement of its facilities, allowing it to cater efficiently to domestic and international markets, including North America, Europe, and emerging economies. The company's revenue streams are largely driven by the sales of its extensive product portfolio, which includes key therapeutic areas like over-the-counter (OTC) brands and prescription medications. By maintaining a diversified product line and emphasizing high-volume, low-margin products, Granules India continually fortifies its market position while sustaining a healthy balance between growth and stability.
See Also
What is Granules India Ltd's Cost of Revenue?
Cost of Revenue
-18.2B
INR
Based on the financial report for Sep 30, 2024, Granules India Ltd's Cost of Revenue amounts to -18.2B INR.
What is Granules India Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-9%
Over the last year, the Cost of Revenue growth was 20%. The average annual Cost of Revenue growth rates for Granules India Ltd have been -5% over the past three years , -6% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
